HISAMITSU PHARMACEUTICAL CO., INC.

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2022🗂️ Report periods on file: 2022

In its 2022 reporting, HISAMITSU PHARMACEUTICAL CO., INC. disclosed greenhouse gas emissions of 34.5K tCO2e/year. By scope: Scope 1: 7.9K tCO2e/year; Scope 2: 14.3K tCO2e/year; Scope 3: 98.5K tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
34.5K tCO2e/year
2022
💧
Water Usage
174.0K m3/year
2022
♻️
Waste
3.7K tons/year
2022

📊 Emissions by Scope (2022)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).7.9K tCO2e/year
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.14.3K tCO2e/year
Scope 3Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.).98.5K tCO2e/year

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

🔜 Short-term

  • Reduce CO2 emissions in Scope 1 and 2 by 46% by FY2030 compared to FY2013

📅 Medium-term

  • Reduce CO2 emissions by 46% compared to FY2013 by FY2030 (Scopes 1 and 2)
  • Achieve Carbon Neutrality by FY2050
  • Reduce industrial waste rate by 1.5% by FY2025 compared to FY2020
  • Reduce product complaint incidence to 0.001% or less by FY2025
  • Raise the average value of 8 items in Morale Survey to 5.0 points or more by FY2025

🔭 Long-term

  • Achieve net zero CO2 emissions by FY2050

🌱 ESG Focus Areas

EnvironmentSocialGovernance

⚠️ Challenges & Risks +

  • Rising raw materials and energy prices
  • Escalating environmental issues
  • Declining birthrate and aging population
  • Growing health consciousness
  • Drug quality and supply concerns
  • Reinforcement and revision of pharmaceutical regulations in Japan and overseas
  • Impact from fluctuations in the cost of raw materials, packaging materials, etc. as well as exchange rates
  • Dependence on external sources for the procurement of raw materials
  • Malfunction in the procurement of raw materials due to climate change
  • Changes in supply chain environment and the emergence of human rights-related risks

📋 Report Information

Reporting Period: 2022
Frameworks: International Integrated Reporting Framework, TCFD, SDGs, SASB